Role of Nanotechnology in Pharmaceutical Product Development

Devalapally, Harikrishna; Chakilam, Ananthsrinivas; Amiji, Mansoor M.

doi:10.1002/jps.20875

Cited by 205 publications

(154 citation statements)

References 126 publications

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…The materials are often polymers of drug or carrier substances previously used in parenteral drug administration but now formulated as nano-scale material (particles, liposomes, nanocapsules, micelles, dendrimers and nanoplexes). 27,28 The bulk of the applications in this area are formulations (e.g., Nanoedge and NanoCrystal platforms for increasing oral delivery) where the extreme surface area to mass ratios of nanomaterial result in refined control of drug delivery, or nanoformulation surfaces improve solubility or permeability in biological systems. In other cases, nano-sized drugs appear to have enhanced and/or targeted tissue biodistribution and have surface properties designed to reduce RE cell uptake.…”

Section: Other Nanomaterialsmentioning

confidence: 99%

Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots

Riviere

2008

WIREs Nanomed Nanobiotechnol

120

View full text Add to dashboard Cite

A full understanding of the pharmacokinetic parameters describing nanomaterial disposition in the body would greatly facilitate development of a firm foundation upon which risk assessment could be based. This review focuses on the disposition of carbon based fullerenes and nanotubes, as well as quantum dots (QD) after parenteral administration to primarily rodents. The common theme across all particle types is that a major determinant of nanomaterial disposition is the degree of interaction with the reticuloendothelial (RE) cell system. Small water-soluble particles evading this system may be excreted by the kidney. Larger particles and those with the proper surface charge may get targeted to RE cells in the liver, spleen and other organs. Most nanomaterial kinetics are characterized by relatively short blood half-lives reflecting tissue extraction and not by clearance from the body. In fact, another common attribute to nanomaterial kinetics is retention of particles in the body. Finally, unlike many small organic drugs, nanomaterials may preferentially be trafficked in the body via the lymphatic system that has obvious immunological implications . T he technological and biomedical advancements inherent to the application of nanomaterials are becoming increasingly evident. In the field of medical applications, a thorough understanding of their pharmacokinetic properties is crucial for their safe and efficacious application. From the perspective of characterizing potential adverse effects, these data are also required for quantitative risk assessments to define the toxicology of the material. Pharmacokinetics is defined as the science of quantifying the rate and extent of the absorption, distribution, metabolism and elimination (ADME) of chemicals and drugs in the body using mathematical modeling approaches. The aim of pharmacokinetics is to relate drug dose or chemical exposure to biological effect. Pharmacokinetics has developed distinct sets of models and parameters which have been useful to describe and predict drug and chemical disposition, and also have specific

show abstract

Section: Other Nanomaterialsmentioning

confidence: 99%

Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots

Riviere

2008

WIREs Nanomed Nanobiotechnol

120

View full text Add to dashboard Cite

show abstract

“…Particularly, in the case of anticancer drugs, such features ultimately lead to inadequate delivery of effective therapeutic drug concentrations to tumor tissue and/or unacceptable toxic effects (Andresen et al, 2005;Cattel et al, 2003). Therefore, it is crucial to develop nanotechnology-based platforms (lipid or polymer-based nanocarriers such as liposomes, micelles, polymeric nanoparticles or dendrimers) to promote and control delivery of some anticancer drugs to tumors (Devalapally et al, 2007;Peer et al, 2007;Dutta, 2007) (Fig. 3).…”

Section: Different Types Of Nanoparticlesmentioning

confidence: 99%

“…Nanoparticles with medical applications differ in terms of structure, size and composition, thus resulting in different characteristics, namely drug loading capacity, physical stability and targeted delivery ability (Haley & Frenkel, 2008). It is beyond the scope of this chapter to review the current drug delivery nanocarriers since they have been widely reviewed in recent publications (Devalapally et al, 2007;Peer et al, 2007;Dutta, 2007;Haley & Frenkel, 2008;Lammers et al, 2008;Cho et al, 2008;Alexis et al, 2008). Therefore, in this chapter an overview will be restricted to liposomes, since these are probably the most used drug delivery system for small drug molecules.…”

Section: Different Types Of Nanoparticlesmentioning

confidence: 99%

Combination Chemotherapy in Cancer: Principles, Evaluation and Drug Delivery Strategies

Pinto¹,

Moreira²,

Simões³

2011

Current Cancer Treatment - Novel Beyond Conventional Approaches

View full text Add to dashboard Cite

“…Protein-based nanoparticulate drug delivery systems are defined as proteins being biodegradable, biocompatible, very versatile molecules, and can be used as drug carriers [19]. A protein-based nanoparticulate drug delivery system is already in the market but protein macromolecules offer many advantages over their synthetic counterparts (synthetic polymers that are commonly used as drug carriers).…”

Section: Nanoparticulate Drug Delivery Systemmentioning

confidence: 99%

Shell-Nanostructured Materials for Biopharmacy and Biomedicine

Mirjanić¹,

Tomić-Šetrajčić²,

Šetrajčić³

2011

View full text Add to dashboard Cite

Based on our research in ultrathin crystal structures performed so far, superlattices, Q-wires and Q-dots, we will consider the materials that can act as carriers for medicines and tagged substances. For this purpose we established a shell-model of ultrathin molecular crystals and investigated their dielectric, particularly optic characteristics. We conducted this research with the help of two-time dependent Green's function method, adjusted to ultrathin crystalline structure analysis. It is shown that specific resonant absorption lines appear in these structures, the number of which depends on crystal layers position and on values of parameters on shell-structure boundary surfaces. The absorption of electromagnetic radiation declines in infrared part and its detection is a relatively easy process.In this paper we will analyze application of nanomaterials in biomedicine, that is to say we will present the recent accomplishments in basic and clinical nanomedicine. Achieving full potential of nanomedicine may be years of even decades away, however, potential advances in drug delivery, diagnosis, and development of nanotechnology-related drugs start to change the landscape of medicine. Site-specific targeted drug delivery (made possible by the availability of unique delivery platforms, such as dendrimers, nanoparticles and nanoliposomes) and personalized medicine (result of the advance in pharmacogenetics) are just a few concepts on the horizon of research. In this paper, especially, we have analyzed the changes in basic physical properties of spherical-shaped nanoparticles that can be made in several (nano)layers and have, at the same time, multiple applications in medicine.

show abstract

Role of Nanotechnology in Pharmaceutical Product Development

Cited by 205 publications

References 126 publications

Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots

Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots

Combination Chemotherapy in Cancer: Principles, Evaluation and Drug Delivery Strategies

Shell-Nanostructured Materials for Biopharmacy and Biomedicine

Contact Info

Product

Resources

About